Recent Quotes (30 days)

You have no recent quotes
chg | %

Ocular Therapeutix Inc  

(Public, NASDAQ:OCUL)   Watch this stock  
Find more results for OCUL
-0.38 (-8.12%)
After Hours: 4.30 0.00 (0.00%)
Nov 21, 4:30PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.20 - 4.78
52 week 4.20 - 11.91
Open 4.77
Vol / Avg. 712,440.00/322,679.00
Mkt cap 124.94M
P/E     -
Div/yield     -
EPS -2.27
Shares 29.44M
Beta 1.53
Inst. own 54%
Nov 7, 2017
Q3 2017 Ocular Therapeutix Inc Earnings Call - Webcast
Nov 7, 2017
Q3 2017 Ocular Therapeutix Inc Earnings Release
Sep 25, 2017
Ocular Therapeutix Inc at Cantor Fitzgerald Global Healthcare Conference - Webcast
Sep 12, 2017
Ocular Therapeutix Inc at Rodman & Renshaw Global Investment Conference
Sep 11, 2017
Ocular Therapeutix Inc at Morgan Stanley Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -2976.48% -2369.00%
Operating margin -2905.55% -2296.03%
EBITD margin - -2249.34%
Return on average assets -86.68% -48.26%
Return on average equity -148.76% -63.14%
Employees 118 -
CDP Score - -


15 Crosby Dr
BEDFORD, MA 01730-1401
United States - Map
+1-781-8953235 (Phone)
+1-781-3574001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Officers and directors

Amarpreet Sawhney Ph.D. Executive Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Antony Charles Mattessich President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Donald D. Notman Jr. Chief Financial Officer
Bio & Compensation  - Reuters
James Fortune Chief Operating Officer
Age: 58
Bio & Compensation  - Reuters
Daniel M. Bollag Ph.D. Senior Vice President - Regulatory Affairs, Pharmacovigilance and Quality
Age: 56
Bio & Compensation  - Reuters
Michael H. Goldstein M.D. Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Jaswinder S. Chadha Director
Age: 49
Bio & Compensation  - Reuters
W. James O'Shea Director
Age: 67
Bio & Compensation  - Reuters
Jeffrey S. Heier M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Richard L. Lindstrom M.D. Independent Director
Age: 69
Bio & Compensation  - Reuters